University at Buffalo experts in the Division of Gastroenterology, Hepatology and Nutrition are contributing co-authors of HCV Next, the first multidisciplinary publication focused exclusively on the hepatitis C virus.
Research co-authored by Andrew H. Talal, MD, shows that injection drug users who are enrolled in a treatment program want to be educated about hepatitis C virus (HCV) and are willing to be treated.
A study led by Andrew H. Talal, MD, is the first to trace in real time how the drug telaprevir inhibits viral replication in the liver and clears hepatitis C virus (HCV) from the cells and plasma of infected patients.
Award-winning participants in the Department of Medicine’s second annual Research Day are studying diverse topics, including disease processes for atrial fibrillation; treatments for leukemia, diabetes and COPD; and the need for cortisol.
University at Buffalo graduate clinical trainees can simultaneously complete their residency or fellowship along with a new, specialized Master of Business Administration (MBA) degree — the first dual program of its kind in New York State and one of only a few in the nation.
Forty-three outstanding medical students, residents, fellows and faculty members have been inducted into the University at Buffalo’s Richard Sarkin Medical Emeritus Faculty Chapter of the Gold Humanism Honor Society (GHHS).
Contrary to physicians’ expectations, when patients with irritable bowel syndrome (IBS) rated their overall health, the severity of their symptoms played only a modest role in their assessments, a University at Buffalo study has found.
Award-winning participants in the Department of Medicine’s inaugural Research Day are studying diverse topics, including burnout, cold medications, a new-found anti-bacterial agent and a better leukemia treatment.
Import medical school events to your personal calendar. Customize by selecting different event categories and receive automatic reminders of the school events that matter most to you.